{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:17:30Z","timestamp":1792790250990,"version":"4.5.0"},"reference-count":35,"publisher":"Korean Diabetes Association","issue":"5","license":[{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Takeda Pharmaceutical Company limited, Korea"}],"content-domain":{"domain":["e-dmj.org"],"crossmark-restriction":true},"short-container-title":["Diabetes Metab J"],"published-print":{"date-parts":[[2022,9,30]]},"abstract":"<jats:p>Background: The choice of an optimal oral hypoglycemic agent in the initial treatment periods for type 2 diabetes mellitus (T2DM) patients remains difficult and deliberate. We compared the efficacy and safety of glimepiride (GLIM), alogliptin (ALO), and alogliptin-pioglitazone (ALO-PIO) in poorly controlled T2DM patients with drug-na\u00efve or metformin failure.Methods: In this three-arm, multicenter, open-label, randomized, controlled trial, poorly controlled T2DM patients were randomized to receive GLIM (&lt;i&gt;n&lt;\/i&gt;=35), ALO (&lt;i&gt;n&lt;\/i&gt;=31), or ALO-PIO (&lt;i&gt;n&lt;\/i&gt;=33) therapy for 24 weeks. The primary endpoint was change in the mean glycosylated hemoglobin (HbA1c) levels at week 24 from baseline. Secondary endpoints were changes in HbA1c level at week 12 from baseline, fasting plasma glucose (FPG) levels, lipid profiles at weeks 12 and 24, and parameters of glycemic variability, assessed by continuous glucose monitoring for 24 weeks.Results: At weeks 12 and 24, the ALO-PIO group showed significant reduction in HbA1c levels compared to the ALO group (\u20130.96%\u00b10.17% vs. \u20130.37%\u00b10.17% at week 12; \u20131.13%\u00b10.19% vs. \u20130.18%\u00b10.2% at week 24). The ALO-PIO therapy caused greater reduction in FPG levels and significant increase in high-density lipoprotein cholesterol levels at weeks 12 and 24 than the ALO therapy. Compared to low-dose GLIM therapy, ALO-PIO therapy showed greater improvement in glycemic variability. The adverse events were similar among the three arms.Conclusion: ALO-PIO combination therapy during the early period exerts better glycemic control than ALO monotherapy and excellency in glycemic variability than low-dose sulfonylurea therapy in uncontrolled, drug-na\u00efve or metformin failed T2DM patients.<\/jats:p>","DOI":"10.4093\/dmj.2021.0183","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T03:26:11Z","timestamp":1647487571000},"page":"689-700","update-policy":"https:\/\/doi.org\/10.4093\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study"],"prefix":"10.4093","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8958-7164","authenticated-orcid":true,"given":"Hae Jin","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In Kyung","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu Yeon","family":"Hur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Kyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Hyun","family":"Noh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Wan","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Seok","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Jung","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0740-8116","authenticated-orcid":true,"given":"Sung Hee","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2567","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-002-1009-0"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0806470"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-011-0002-3"},{"key":"ref4","first-page":"402","volume-title":"Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes","author":"Deacon","year":"2008"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2337\/dcs13-2011"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2337\/dcs15-3007"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)32131-2"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2243"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2174\/1874467211205020272"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2014.08.005"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-019-0425-y"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-020-01085-6"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2018.01.031"},{"key":"ref14","first-page":"840","volume-title":"Sulfonylureas and their use in clinical practice","author":"Sola","year":"2015"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2014.0378"},{"key":"ref16","first-page":"773","volume-title":"Banting lecture: from the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus","author":"Defronzo","year":"2009"},{"key":"ref17","first-page":"671","volume-title":"Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment","author":"Triplitt","year":"2010"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra041001"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/med.0b013e3280a02f65"},{"key":"ref20","first-page":"415","volume-title":"Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in <italic>db\/db<\/italic> mice","author":"Moritoh","year":"2009"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2008.11.017"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2010.12.021"},{"key":"ref23","first-page":"2406","volume-title":"Initial combination therapy with alogliptin and pioglitazone in drug-naive patients with type 2 diabetes","author":"Rosenstock","year":"2010"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2217\/cer.13.87"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2004.05.001"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12869"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3803\/enm.2017.32.2.241"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12102"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2015.05.025"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.7.1547"},{"key":"ref31","first-page":"15","volume-title":"Management of co-existing diabetes mellitus and dyslipidemia: defining the role of thiazolidinediones","author":"Florkowski","year":"2002"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.14218\/jcth.2017.00050"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2016.9607"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3892\/br.2016.569"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12555"}],"container-title":["Diabetes &amp; Metabolism Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-dmj.org\/upload\/pdf\/dmj-2021-0183.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-dmj.org\/journal\/view.php?doi=10.4093\/dmj.2021.0183","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-dmj.org\/upload\/pdf\/dmj-2021-0183.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,25]],"date-time":"2022-09-25T20:39:15Z","timestamp":1664138355000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-dmj.org\/journal\/view.php?doi=10.4093\/dmj.2021.0183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"URL":"https:\/\/doi.org\/10.4093\/dmj.2021.0183","relation":{},"ISSN":["2233-6079","2233-6087"],"issn-type":[{"value":"2233-6079","type":"print"},{"value":"2233-6087","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,30]]},"assertion":[{"value":"2021-08-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-17","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-30","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}